Cargando…

Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer

PURPOSE: Effective preoperative regimens and biomarkers for pancreatic ductal adenocarcinoma (PDAC) are lacking. We prospectively evaluated fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX)-based treatment and imaging-based biomarkers for borderline resectable PDAC. METHODS: Eligibl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koay, Eugene J., Katz, Matthew H.G., Wang, Huamin, Wang, Xuemei, Prakash, Laura, Javle, Milind, Shroff, Rachna, Fogelman, David, Avila, Santiago, Zaid, Mohamed, Elganainy, Dalia, Lee, Yeonju, Crane, Christopher H., Krishnan, Sunil, Das, Prajnan, Fleming, Jason B., Lee, Jeffrey E., Tamm, Eric P., Bhosale, Priya, Lee, Jeffrey H., Weston, Brian, Maitra, Anirban, Wolff, Robert A., Varadhachary, Gauri R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Original Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446521/ https://www.ncbi.nlm.nih.gov/pubmed/32914036 http://dx.doi.org/10.1200/PO.19.00001

Ejemplares similares

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
por: Javle, Milind M, et al.
Publicado: (2010)

Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer
por: Wang, Charles X., et al.
Publicado: (2022)

Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy
por: Crane, Christopher H., et al.
Publicado: (2009)

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
por: Katz, Matthew H. G., et al.
Publicado: (2010)

Imaging‐based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy
por: Amer, Ahmed M., et al.
Publicado: (2018)

Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
por: Fogelman, David R., et al.
Publicado: (2014)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
por: Tong, Yi Tat, et al.
Publicado: (2023)

PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer
por: Douglas, Julia E., et al.
Publicado: (2022)

Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC
por: Colbert, Lauren E., et al.
Publicado: (2017)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study
por: Zaid, Mohamed, et al.
Publicado: (2020)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

Reirradiation to the abdomen for gastrointestinal malignancies
por: Haque, Waqar, et al.
Publicado: (2009)

Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma
por: Liu, Qingqing, et al.
Publicado: (2017)

Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients
por: Mohindroo, Chirayu, et al.
Publicado: (2021)

IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer
por: Moningi, Shalini, et al.
Publicado: (2019)

Quantitative imaging to evaluate malignant potential of IPMNs
por: Hanania, Alexander N., et al.
Publicado: (2016)

Concurrent capecitabine and upper abdominal radiation therapy is well tolerated
por: Das, Prajnan, et al.
Publicado: (2006)

The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer
por: Perri, Giampaolo, et al.
Publicado: (2020)

A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer
por: Katz, Matthew, et al.
Publicado: (2015)

Patient-Reported Outcomes After Chemoradiation in Patients With Anal Cancer: A Qualitative Analysis
por: Corrigan, Kelsey L., et al.
Publicado: (2022)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
por: Goldstein, Jennifer B., et al.
Publicado: (2017)

Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C(max) and improved tolerability, in patients with solid tumors
por: Ajani, Jaffer A., et al.
Publicado: (2020)

Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
por: Chung, Moon Jae, et al.
Publicado: (2018)

Change of telomerase activity in rectal cancer with chemoradiation therapy.
por: Kim, H. R., et al.
Publicado: (2000)

Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience
por: Bhutani, Manoop S., et al.
Publicado: (2019)

Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX
por: Hyung, J., et al.
Publicado: (2022)

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
por: Churi, Chaitanya R., et al.
Publicado: (2014)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience
por: Lee, Jongchan, et al.
Publicado: (2018)

Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma
por: De, Brian, et al.
Publicado: (2021)

Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
por: Maman, Yossi, et al.
Publicado: (2023)

3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma
por: Kang, Ya’an, et al.
Publicado: (2022)

Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Esophagectomy for Esophageal Cancer
por: Kim, Juwan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i979qii9u4jvlkj6q38p4lk1no